[PDF] European CHMP recommends approval of enzalutamide (Xtandi®) for prostate cancer

Source:
European Medicines Agency - EMA
Publisher:
European Medicines Agency
Publication date:
26 April 2013

Abstract

The EMA’s CHMP has adopted a positive opinion recommending approval of enzalutamide (Xtandi®) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.